New Publication on Etelcalcetide in Hemodialysis Patients

A study on etelcalcetide was published on October 12, 2026, in the journal Kidney360. The publication is titled "Real-World Etelcalcetide Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients with Inadequate Cinacalcet Response or Intolerance: Prospective Observational Study." Etelcalcetide is an approved compound. The study is described as a prospective observational study. It focuses on patients with secondary hyperparathyroidism undergoing hemodialysis who had an inadequate response to cinacalcet or who could not tolerate it. No findings, outcomes, or conclusions from the study have been provided at this time. Readers interested in the details of the study design or its results should consult the full publication directly through the journal. This brief reports only that the publication exists and the context described in its title. For additional background on etelcalcetide, including its approved regulatory status and general information, readers can refer to the compound overview.